DelNova: Addressing complications from Botox (217)

Episode 17 May 24, 2022 00:19:03
DelNova: Addressing complications from Botox (217)
Innovation4Alpha
DelNova: Addressing complications from Botox (217)

May 24 2022 | 00:19:03

/

Show Notes

DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications. 

Other Episodes

Episode 5

February 09, 2022 00:43:54
Episode Cover

Jaffar Raza, MD - Opportunities, Cost Management and Technology (205)

Jaffar Raza, MD is a board certified Interventional Cardiologist affiliated with Lenox Hill, Hackensack and Holy name hospitals. He completed his residency in Internal...

Listen

Episode 11

July 18, 2021 00:23:48
Episode Cover

Startup Profile: Eyetamins (011)

Eyetamins is a healthcare technology and life sciences company focused on therapeutics and consumer innovations in the $200B eye health and wellness space. They...

Listen

Episode 18

May 29, 2022 00:24:23
Episode Cover

Tommy Barletta: Governmental Affairs Advisor to Startups (218)

Mr. Barletta is the founder of an advisory firm based in Washington DC called Jones Point. The firm possesses a unique combination of more...

Listen